Pfizer Inc SEC filings PFE
Pfizer Inc has 1,000 filings in SEC EDGAR's recent list, going back to Feb 26, 2021. Its latest annual report, Form ARS, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 27, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Apr 27, 2026 | Apr 23, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 3, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 16, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Other events
|
Nov 21, 2025 | Nov 18, 2025 |
| 8-K |
Current report
Other events
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Other events
|
May 19, 2025 | May 14, 2025 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Apr 29, 2025 | Apr 29, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Apr 28, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 4, 2025 | Feb 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 17, 2024 | Dec 17, 2024 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2024 | Oct 29, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 10, 2024 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2024 | Jul 30, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 26, 2024 | Jul 24, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2024 | Jul 9, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
May 22, 2024 | May 22, 2024 |
| 8-K |
Current report
Results of operations
|
May 1, 2024 | May 1, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Apr 29, 2024 | Apr 25, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 30, 2024 | Jan 30, 2024 |
| 8-K |
Current report
Other events
|
Jan 10, 2024 | Jan 10, 2024 |
| 8-K/A |
Amended current report
Acquisition or sale of assets, Regulation FD disclosure
|
Dec 14, 2023 | Dec 14, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Dec 14, 2023 | Dec 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 13, 2023 | Dec 13, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 12, 2023 | Dec 7, 2023 |
| 8-K |
Current report
Results of operations
|
Oct 31, 2023 | Oct 31, 2023 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure
|
Oct 13, 2023 | Oct 13, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 1, 2023 | Aug 1, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2023 | Jul 21, 2023 |
| 8-K |
Current report
Other events
|
May 19, 2023 | May 16, 2023 |
| 8-K |
Current report
Other events
|
May 15, 2023 | May 12, 2023 |
| 8-K |
Current report
Results of operations
|
May 2, 2023 | May 2, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 1, 2023 | Apr 27, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Mar 13, 2023 | Mar 12, 2023 |
| 8-K |
Current report
Other events
|
Feb 21, 2023 | Feb 21, 2023 |
| 8-K |
Current report
Results of operations
|
Jan 31, 2023 | Jan 31, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 13, 2022 | Dec 9, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2022 | Jul 28, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 10, 2022 | May 9, 2022 |
| 8-K |
Current report
Results of operations
|
May 3, 2022 | May 3, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 2, 2022 | Apr 28, 2022 |
| 8-K |
Current report
Results of operations
|
Apr 20, 2022 | Apr 20, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 12, 2022 | Apr 11, 2022 |
| 8-K |
Current report
Other events
|
Mar 29, 2022 | Mar 24, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 8, 2022 | Feb 8, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 15, 2021 | Dec 9, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 19, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2021 | Nov 2, 2021 |
| 8-K |
Current report
Other events
|
Aug 18, 2021 | Aug 16, 2021 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2021 | Jul 28, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 9, 2021 | Jul 6, 2021 |
| 8-K |
Current report
Results of operations
|
May 4, 2021 | May 4, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Apr 26, 2021 | Apr 22, 2021 |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PFE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 78003
- Former names
- PFIZER INC (until Nov 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.